90% of diabetic blindness is preventable with annual screening and timely treatment. Diabetic retinopathy causes no symptoms until it is advanced — by the time your vision blurs, significant and often irreversible damage has already occurred.
The International Clinical DR Severity Scale grades retinopathy from no DR to proliferative. Your grade determines screening frequency and whether treatment is needed now.

No abnormalities visible on dilated fundus examination. Still requires annual screening — duration of diabetes, HbA1c control, hypertension, and microalbuminuria determine when DR will first appear. Most diabetics develop some degree of DR after 20 years of disease, even with good control.

Microaneurysms only — small outpouchings of retinal capillary walls. These are the earliest ophthalmoscopic sign of diabetic retinopathy. Vision is unaffected. No treatment needed — but systematic blood sugar, blood pressure, and lipid control are critical to slowing progression.

More than microaneurysms — dot and blot haemorrhages, hard exudates, soft exudates (cotton wool spots). OCT macula is added to the protocol to detect early CSME (clinically significant macular oedema). If CSME is present, anti-VEGF treatment begins regardless of visual acuity.

The "4-2-1 rule": haemorrhages in all 4 quadrants, venous beading in ≥2 quadrants, or intraretinal microvascular abnormalities (IRMA) in ≥1 quadrant. 52% progress to PDR within 1 year without treatment. 3-monthly review and consider focal laser or anti-VEGF.

New blood vessel growth (neovascularisation) on the disc or elsewhere — fragile vessels that bleed into the vitreous and cause tractional retinal detachment. Requires prompt pan-retinal photocoagulation (PRP laser) and/or anti-VEGF. Vitrectomy if vitreous haemorrhage or traction detachment occurs.

Fluid accumulation in the macula — the centre of detailed vision — can occur at any stage of DR. It is the most common cause of vision loss in diabetics. OCT detects subclinical oedema before visual symptoms appear. Anti-VEGF injections (Avastin/Lucentis) achieve vision gains in the majority of treated eyes.
Our diabetic screening follows the ICDR Severity Scale grading protocol — the same standard used in the UK NHS and AIIMS diabetic retinopathy programs. You receive a written graded report to share with your endocrinologist.
HbA1c, duration of diabetes, blood pressure, lipid profile, and renal function (microalbuminuria) — all are independent risk factors for DR progression. We document these at every visit to assess risk trajectory, not just retinal findings in isolation.
LogMAR visual acuity in each eye. Intraocular pressure (diabetes is an independent glaucoma risk factor) — so every diabetic retinal screen includes glaucoma screening.
Dilating drops (tropicamide 1%) followed by 45° or wide-field fundus photography — captures haemorrhages, exudates, new vessels, and disc appearance. Images are stored for year-on-year comparison, providing objective evidence of stability or progression.
Cross-sectional imaging detects subretinal and intraretinal fluid before visual symptoms appear. Central subfield thickness is measured — a value above 320 microns in the presence of DR triggers immediate anti-VEGF referral regardless of visual acuity.
A graded report with DR stage, macular status, IOP, and recommended recall interval is provided at the end of every visit. A copy is sent to your treating physician. Recall intervals: Grade 0–1 = 12 months, Grade 2 = 6 months, Grade 3–4 = 3 months or urgent treatment.

We don't just examine your eyes — we grade to the international standard, store images, and compare year-on-year. If your retinopathy is progressing, you will know precisely how fast and what to do about it.
International Clinical Diabetic Retinopathy Severity Scale grading at every visit — the same standard used in structured national screening programs. You receive a written grade, not just "come back in a year".
Fundus photographs are stored and compared year-on-year. OCT macula detects CSME before you lose vision — so treatment can begin at the optimal time, not after irreversible damage.
DR grade correlates directly with systemic disease control. Our reports include recommendations for HbA1c targets, blood pressure management, and lipid control — shared with your endocrinologist so eye findings inform systemic management, not just the other way around.
Not all retinal checks are equal. The difference between a structured annual screen and an opportunistic look is the difference between early detection and presentation with vitreous haemorrhage.
| Screening Type | Supreme Elite Structured Screen | Hospital OPD Check | General Optician | No Screening |
|---|---|---|---|---|
| ICDR Grading | Yes — every visit | Variable | Rarely | None |
| Retinal Photography | Yes — stored & compared | Sometimes | Not typically | None |
| OCT Macula | Yes (Grade 2+) | If requested | Rarely available | None |
| Written Report to GP/Endocrinologist | Yes — every screen | Variable | No | None |
| Structured Recall System | Yes — grade-based interval | Variable | No | None |
| Cost per Screen | ₹800 | Free (wait times) | ₹500–₹800 (no OCT) | ₹0 (but sight-threatening) |
If you have diabetes — Type 1, Type 2, gestational, or steroid-induced — you need annual dilated retinal examination. No exceptions. Book now: +91 96774 73344
Bring your most recent HbA1c result if you have it.
Annual screening takes 45 minutes. Arrange a driver — dilating drops will blur your vision for several hours.